Foretinib

Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.

Product Specifications

CAS Number

[849217-64-7]

Product Name Alternative

XL880; GSK1363089; GSK089; EXEL-2880

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Met/HGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Foretinib.html

Concentration

10mM

Purity

99.59

Solubility

DMSO : 75 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O

Molecular Formula

C34H34F2N4O6

Molecular Weight

632.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69 (20), 8009-8016.|[2]Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.|[3]Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16 (13), 3507-3516.